Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data
Related Experiment Video
Updated: Feb 6, 2026

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
Joshua J Gagne1, Theodore Tsacogianis1, Sara Bruce Wirta2
1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02120, USA.
Insights
Early users of sacubitril/valsartan for heart failure (HF) were younger and often had prior HF treatment. These patients resembled those with HF with reduced ejection fraction and used other HF medications.
Area of Science:
- Cardiology
- Pharmacology
- Real-world evidence
Background:
- Sacubitril/valsartan is a novel treatment for heart failure (HF).
- Understanding early adoption patterns is crucial for optimizing HF management.
Purpose of the Study:
- To characterize early users of sacubitril/valsartan in a large US electronic health records database.
- To compare early sacubitril/valsartan users with other heart failure patient cohorts.
Main Methods:
- Retrospective analysis of a US electronic health records database.
- Identification of three heart failure cohorts: sacubitril/valsartan users, HF with reduced ejection fraction (HFrEF), and standard therapy (ACEi/ARB + beta-blocker).
Main Results:
- Sacubitril/valsartan patients were younger compared to other HF cohorts.
- The mean age of sacubitril/valsartan users increased over the initial 15 months of market availability.
- Most sacubitril/valsartan initiators had prior heart failure treatment.
Conclusions:
- Early sacubitril/valsartan users largely mirrored the characteristics of the HFrEF cohort.
- Concurrent use of other heart failure medications was common among sacubitril/valsartan patients.
Aim:
We examined characteristics of early sacubitril/valsartan users in a large US electronic health records database.
Patients & Methods:
We identified three cohorts of patients with heart failure (HF): sacubitril/valsartan patients with a prior HF diagnosis; patients with HF with reduced ejection fraction; and patients with HF treated with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker and a β-blocker.
Results:
Sacubitril/valsartan patients were younger than patients in the other cohorts; the mean age of sacubitril/valsartan patients increased by 2 years in the first 15 months of marketing. Most sacubitril/valsartan patients had prior use of HF treatment.
Conclusion:
Overall, sacubitril/valsartan patients resembled those in the HF with reduced ejection fraction cohort, and commonly used other drugs for HF.
Related Concept Videos
Data Reporting and Recording
Purpose of Health Records I
Here's a breakdown of how health records serve these purposes:
Purpose of Health Records II
Characteristics of Life
Design Consideration
The factor of safety is another key...
Tensile Strength Considerations of Concrete
The dimensions and shape of a concrete specimen...

